Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.03 EUR
Change Today +0.006 / 27.27%
Volume 15.0K
E4N On Other Exchanges
As of 7:59 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

suda ltd (E4N) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/29/14 - €0.05
52 Week Low
06/30/15 - €0.0070
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SUDA LTD (E4N)

Related News

No related news articles were found.

suda ltd (E4N) Related Businessweek News

No Related Businessweek News Found

suda ltd (E4N) Details

Suda Limited engages in the pharmaceutical development of drug delivery technologies in Australia. The company is developing ArTiMist malaria, a sub-lingual spray that has completed Phase III clinical trial for the treatment of p. falciparum severe paediatric malaria. Its product candidates also include SUD-001, a honey-flavoured oral spray formulation of sumatriptan; SUD-002, a mint-flavoured oral spray formulation of ondansetron to treat nausea and vomiting induced by chemotherapy or radiotherapy, and other post-operative settings; and SUD-003, an oral spray formulation of sildenafil sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction. In addition, the company is developing SUD-004, an oral spray formulation of sildenafil to treat pulmonary arterial hypertension in adults; and SUD-005, a strawberry/mint-flavoured oral spray formulation of midazolam for the treatment of pre-procedure anxiety in imaging and dental procedures, and in the treatment of epileptic seizures. Further, it distributes medical devices and consumables to hospitals, aged care facilities, pharmacies, mining companies, and other healthcare providers. The company was formerly known as Eastland Medical Systems Limited and changed its name to Suda Limited in December 2012. Suda Limited is based in Osborne Park, Australia.

27 Employees
Last Reported Date: 09/26/14

suda ltd (E4N) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: A$238.4K
Chief Financial Officer, Company Secretary, E...
Total Annual Compensation: A$193.8K
Chief Business Officer
Total Annual Compensation: A$116.0K
General Manager of Westcoast
Total Annual Compensation: A$133.8K
Compensation as of Fiscal Year 2014.

suda ltd (E4N) Key Developments

SUDA LTD Announces Clinical Advisory Board Appointments

SUDA LTD announced the appointment of three erectile dysfunction specialists to its Clinical Advisory Board for SUD-003, the company's oral spray of sildenafil citrate for the treatment of erectile dysfunction. These experts are providing advice and guidance to SUDA on the pivotal development plan, which will be presented to the US FDA. The three appointments to the CAB are Dr. William E Pullman, Dr. David J Ralph and Associate Professor Eric Chung. Dr. Pullman is a physician with over 25 years' global experience matured in both large and small pharmaceutical companies, handling small molecules and biotechnology products across all phases of drug development. His industrial positions included Pfizer, Eli Lilly and Sanofi-Aventis where he set strategies and executed operational plans; managed drug discovery and development; supported regulatory approval and commercialization of many drugs. Eric Chung is a consultant urological surgeon working in Brisbane Australia and a certified Fellow of the Royal Australasian College of Surgeons and Urological Society of Australia and New Zealand. He is the current Chair of the Andrology Group in USANZ and serves on many national advisory committees and international organizations. Dr. Ralph is an internationally recognized urological microsurgeon and an Honorary Senior Lecturer at the Institute of Urology and Nephrology, University College London. He also teaches at the Royal College of Surgeons Microsurgery for Andrologists.

Suda Ltd Announces Consolidated Earnings Results for the Six Months Ended December 31, 2014

Suda Ltd. announced consolidated earnings results for the six months ended December 31, 2014. For the period, the company reported revenues of AUD 2,999,153 compared with AUD 6,241,998 for the same period a year ago. Loss before income tax was AUD 1,957,350 compared with AUD 331,847 for the same period a year ago. Loss and total comprehensive loss attributable to owners of the parent was AUD 1,944,854 or 0.20 cents per basic and diluted share compared with AUD 331,847 or 0.04 cents per basic and diluted share for the same period a year ago. Net cash used in operations was AUD 1,847,677 compared with AUD 1,374,008 for the same period a year ago. Payment for development of products was AUD 688,446 compared with AUD 1,471,326 for the same period a year ago. Payment for property, plant & equipment was AUD 85,254 compared with AUD 94,138 for the same period a year ago.

Suda Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015

Suda Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
E4N:GR €0.03 EUR +0.006

E4N Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for E4N.
View Industry Companies

Industry Analysis


Industry Average

Valuation E4N Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUDA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at